We propose to create an integrated Leukemia Translational Science Center (LTSC), which will generate, coordinate and lead translational studies in leukemia within ECOG-ACRIN and within the National Clinical Trials Network (NCTN). The LTSC will serve as the central hub for studies of the Leukemia Laboratory Committee (LLC), with the support of the Leukemia Translational Laboratory (LTRL), the Leukemia Tissue Bank (LTB), and a comprehensive Leukemia Data Warehouse. The LTSC is led by E. Paietta, A. Melnick and R. Levine, who collectively lead the LLC, LTRL and LTB. Through these initiatives, they have developed an extensive track record in translational research leadership and implementation of state-of-the-art correlative studies in leukemia biology. The LTSC is further enhanced through its partnership with the New York Genome Center, which provides access to high-throughput genomics technologies, state-of-the-art genomic platforms, computational resources, and the capability to perform extensive, CLIA-certified, clinical genomics assays. In order to maximally accelerate high quality clinical trials based on the most important science, the LTSC will establish an interaction framework that will attract junior and senior clinical investigators, laboratory scientists, computational biologists, biostatisticians and others, and enable them to form synergistic research teams. The LTSC will provide pilot project funding for cross-disciplinary teams to jump-start these projects and an extensive suite of scientific resources, including patient specimens, the LTRL, access to the New York Genome Center, genomic and epigenetic profiling databases, and scientific support. In this way, the LTSC will ensure that translational scientific studies are seamlessly integrated into leukemia clinical trials to identify predictors of response/outcome, identify and test novel therapies, and develop innovative correlative studies to assess response to anti-leukemia therapies. Through these activities, the LTSC expects to transform the standard practice of leukemia care with the development and implementation of personalized diagnostic methods, biomarkers and therapies.
Advances in the treatment of hematologic disorders have been disappointing. The ECOG-ACRIN Leukemia Translational Science Center will create, support, and synergize partnerships between clinical and laboratory investigators and foster the continuous, near-term translation of state-of-the art laboratory studies into clinical trials to improve outcomes for leukemia patients.
| Brown, Fiona C; Still, Eric; Koche, Richard P et al. (2018) MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia. Cancer Discov 8:478-497 |
| Mitchell, Kelly; Barreyro, Laura; Todorova, Tihomira I et al. (2018) IL1RAP potentiates multiple oncogenic signaling pathways in AML. J Exp Med 215:1709-1727 |
| Shih, Alan H; Meydan, Cem; Shank, Kaitlyn et al. (2017) Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia. Cancer Discov 7:494-505 |
| Sanchez-Martin, Marta; Ambesi-Impiombato, Alberto; Qin, Yue et al. (2017) Synergistic antileukemic therapies in NOTCH1-induced T-ALL. Proc Natl Acad Sci U S A 114:2006-2011 |
| Vu, Ly P; Prieto, Camila; Amin, Elianna M et al. (2017) Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. Nat Genet 49:866-875 |
| Roberts, Kathryn G; Gu, Zhaohui; Payne-Turner, Debbie et al. (2017) High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. J Clin Oncol 35:394-401 |
| Cardenas, Mariano G; Oswald, Erin; Yu, Wenbo et al. (2017) The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target. Clin Cancer Res 23:885-893 |
| Zhang, Jinghui; McCastlain, Kelly; Yoshihara, Hiroki et al. (2016) Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat Genet 48:1481-1489 |
| Gu, Zhaohui; Churchman, Michelle; Roberts, Kathryn et al. (2016) Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nat Commun 7:13331 |
| Tan, Su-Fern; Liu, Xin; Fox, Todd E et al. (2016) Acid ceramidase is upregulated in AML and represents a novel therapeutic target. Oncotarget 7:83208-83222 |
Showing the most recent 10 out of 39 publications
